Research Article
Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
Table 3
Pretreatment factors affecting overall survival.
| | | n | mOS | Univariate | Hazard ratio (95% CI) | Multivariate |
| Sex | Male | 39 | 46 | 0.1285 | | | Female | 10 | 23 |
| Age (years) | >76 | 25 | 49 | 0.0325 | 0.4838 (0.1267–1.8480) | 0.2908 | <76 | 24 | 23 |
| Etiology | HCV | 18 | 24 | 0.9782 | | | Cripto | 19 | 46 | Alcol | 10 | — | Others | 2 | 28 |
| Child-Pugh class | 5 | 17 | 48 | 0.0365 | 0.9823 (0.1690–5.7078) | 0.9842 | 6 | 21 | 33 | 7 | 7 | 17 | 8 | 3 | 14 | 9 | 1 | 23 |
| NLR | >2.03 | 25 | 18 | 0.0429 | 11.5283 (2.3361–56.8918) | 0.0028 | <2.03 | 24 | 33 |
| PLR | >87.99 | 25 | 24 | 0.9737 | | | <87.99 | 24 | 33 |
| BCLC stage | B | 34 | 48 | 0.0199 | 1.8542 (0.4128–8.3281) | 0.4229 | C | 15 | 23 |
| Tumor size (cm) | >5 | 26 | 24 | 0.6515 | | | <5 | 23 | 33 |
| Number of tumors | <3 | 25 | 24 | 0.2565 | | | 3–5 | 9 | 17 | >5 | 15 | 46 |
| Extrahepatic spread | Absent | 49 | 28 | — | | | Present | 0 | — |
| Bilobar spread | Absent | 18 | 46 | 0.6596 | | | Present | 31 | 24 |
| Ascites | Absent | 37 | 48 | 0.0964 | | | Present | 12 | 23 |
| Albumin | >3.7 | 25 | — | 0.1210 | | | <3.7 | 24 | 22 |
| Bilirubin | >0.84 | 25 | 23 | 0.2664 | | | <0.84 | 24 | 33 |
| INR | >1.18 | 25 | 22 | 0.0218 | 16.9893 (1.6017–180.2098) | 0.0193 | <1.18 | 24 | — |
| Creatinine | >0.78 | 25 | 24 | 0.7856 | | | <0.78 | 24 | 24 |
| GFR | >94.5 | 25 | 21 | 0.7606 | | | <94.5 | 24 | 24 |
|
|
BCLC = Barcelona Clinic Liver Cancer; Cripto = criptogenetic; GFR = glomerular filtration rate; HCV = hepatitis C virus; INR = International Normalized Ratio; mOS = median overall survival; NLR = neutrophil to lymphocyte ratio; PLR = platelet to lymphocyte ratio.
|